Change over period: —
NSE · METROPOLIS
METROPOLIS
-6.3% from the 52-week high · +33.8% above the low
Metropolis Healthcare Ltd. owns and operates medical laboratories. The company is headquartered in Gurgaon, Haryana and currently employs 4,289 full-time employees. The company went IPO on 2019-04-15. The firm offers a range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and monitoring of the disease. The firm also offers analytical and support services to clinical research organizations for their clinical research projects. Its services include pathology testing services, corporate wellness, lab in hospitals and clinical research services. The firm offers a range of tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company owns a chain of diagnostic centers across India, South Asia, Africa and the Middle East. The firm has spread its footprint across 20 Indian states and over 210 cities.
The short version. METROPOLIS reported revenue of ₹497 crore for Sep 2026, up 15.9% from a year earlier. Net profit was ₹75 crore (up 41.5% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 47.82% in Sep 2026, down 1.58 points over 8 quarters.
1 · The price
How has the stock traded?
METROPOLIS trades 6.3% below its 52-week high and 33.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹497 cr.
Sep 2026 net profit of ₹75 cr.
2.9 pts higher than a year earlier.
Revenue compounded at 12.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 497 | 450 | 425 | 406 | 429 | 386 | 345 | 323 |
| Net profit | 75 | 57 | 51 | 41 | 53 | 45 | 29 | 31 |
| Net margin % | 15.2 | 12.6 | 12.0 | 10.2 | 12.3 | 11.7 | 8.4 | 9.7 |
| EPS (₹) | 3.63 | 2.73 | 2.46 | 2.0 | 2.54 | 2.17 | 1.41 | 1.53 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1646 | 1331 | 1208 | 1148 | 1228 | 998 | 856 | 761 |
| Net profit | 190 | 145 | 128 | 143 | 214 | 183 | 127 | 120 |
| Net margin % | 11.5 | 10.9 | 10.6 | 12.4 | 17.4 | 18.3 | 14.9 | 15.8 |
| EPS (₹) | 9.17 | 7.0 | 6.24 | 6.98 | 10.46 | 8.95 | 6.29 | 5.99 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 12.6% in Mar 2026; debt to equity is 0.01.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 12.6 | 10.9 | 11.7 | 14.5 |
| Return on capital % | 15.7 | 13.3 | 15.1 | 17.3 |
| EBITDA margin % | 25.0 | 23.6 | 24.0 | 26.1 |
| Net margin % | 11.4 | 10.8 | 10.5 | 12.3 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 12.8% | 10.6% |
| Profit CAGR | 10.0% | 0.7% |
4 · The owners
Who holds it, and are they adding?
Down 1.58 pts over 8 quarters.
Down 5.06 pts over 8 quarters.
Up 5.49 pts over 8 quarters.
+12 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.4 | 48.9 | 48.89 | 48.89 | 48.88 | 48.87 | 48.86 | 47.82 | -1.58 |
| FII | 16.73 | 15.29 | 12.83 | 12.52 | 11.69 | 10.43 | 11.03 | 11.67 | -5.06 |
| DII | 30.0 | 30.3 | 32.4 | 33.1 | 34.73 | 35.79 | 35.12 | 35.49 | +5.49 |
| Public | 3.87 | 5.52 | 5.88 | 5.49 | 4.71 | 4.91 | 4.99 | 5.02 | +1.15 |
Mutual fund holdings · Oct 2026
72 schemes hold this stock
60 the month before.
- TATA BUSINESS CYCLE FUND4.54% of NAV
- LIC MF HEALTHCARE FUND3.73% of NAV
- Franklin India Opportunities Fund2.4% of NAV
- Kotak ESG Exclusionary Strategy Fund2.17% of NAV
- TATA CHILDRENS FUND2.11% of NAV
- Franklin India Small Cap Fund2.06% of NAV
- Kotak Small Cap Fund1.94% of NAV
- THE WEALTH COMPANY SMALL CAP FUND1.89% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for METROPOLIS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about METROPOLIS
What is the METROPOLIS share price?
METROPOLIS (METROPOLIS) last closed at ₹562.45, down 0.33% on the day. Its 52-week range is ₹421.75 to ₹602.10.
What is the market cap of METROPOLIS?
METROPOLIS has a market capitalisation of about ₹11,699 crore. Its price-to-earnings ratio is 52.6.
How are METROPOLIS's latest results?
METROPOLIS reported revenue of ₹497 crore for Sep 2026, up 15.9% from a year earlier. Net profit was ₹75 crore (up 41.5% year on year). Return on equity was 12.6% in Mar 2026. Promoter holding was 47.82% in Sep 2026, down 1.58 points over 8 quarters.
Who owns METROPOLIS?
As of Sep 2026, shareholding was: Promoter 47.82%, FII 11.67%, DII 35.49%, Public 5.02%.
How many mutual funds hold METROPOLIS?
72 mutual fund schemes held METROPOLIS in October 2026. That compares with 60 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 19 May 2026 · Interim Dividend - Rs. 1
- 20 Mar 2026 · Bonus issue 3:1
- 11 Nov 2025 · Interim Dividend - Rs. 4
- 17 Nov 2023 · Interim Dividend - Rs. 4
- 23 Feb 2023 · Interim Dividend - Rs. 8
- 21 Feb 2022 · Interim Dividend - Rs. 8
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.